Poly (ADP-ribose) polymerase inhibitors (PARPi) for treating advanced epithelial ovarian cancer
Gene / mechanism
BRCA1/2
PARP inhibition, which prevents repair of DNA damage, particularly in tumours with a tumour or germline BRCA variant or homologous recombination deficiency
Summary
This 2026 update of a Cochrane review assesses PARP inhibitors versus placebo or other anticancer treatments in advanced epithelial ovarian cancer, newly diagnosed or recurrent, based on 24 randomised trials (8,961 participants), 10 of them new; most participants had a tumour and/or germline BRCA variant or tumour homologous recombination deficiency. As maintenance after first-line chemotherapy, PARP inhibitors substantially improve progression-free survival (HR 0.51; high certainty), with an uncertain effect on overall survival (HR 0.80; low certainty) and a 2.66-fold increase in the risk of severe adverse events. In platinum-sensitive relapse, progression-free survival is also markedly improved (HR 0.34) and overall survival probably slightly increased (HR 0.88). In platinum-resistant relapse, PARP inhibitor monotherapy reduces overall survival compared with chemotherapy (HR 1.36; high certainty).
Synthesis written by Geno'X. For the full original abstract, please refer to the source publication.
Analysis
For the cancer geneticist, this synthesis is a reminder that the therapeutic stake of BRCA status lies first in maintenance after platinum response, where the progression-free survival gain is established with high certainty. The overall survival benefit remains uncertain, partly because placebo arms received more PARP inhibitors at relapse, and the excess of severe adverse events weighs in shared decision-making. The abstract does not report separate results for germline carriers, which limits direct translation into genetic counselling.
Analysis by Dr Thibaut Benquey
Why this score?
Clinical impact: 2/3 · Evidence strength: 3/3 · Novelty: 1/2 · Sample size: 1/1 · Publication status: 0/1 → Total: 7/10
Keywords
Every Wednesday · Annotated selection · Free · Unsubscribe anytime